SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-044892
Filing Date
2023-12-14
Accepted
2023-12-14 17:00:49
Documents
54
Period of Report
2023-10-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 687033
2 ex31-1.htm EX-31.1 10415
3 ex31-2.htm EX-31.2 10341
4 ex32-1.htm EX-32.1 4355
5 ex32-2.htm EX-32.2 4337
  Complete submission text file 0001493152-23-044892.txt   3980088

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE bctx-20231031.xsd EX-101.SCH 29944
7 XBRL CALCULATION FILE bctx-20231031_cal.xml EX-101.CAL 33393
8 XBRL DEFINITION FILE bctx-20231031_def.xml EX-101.DEF 155820
9 XBRL LABEL FILE bctx-20231031_lab.xml EX-101.LAB 242412
10 XBRL PRESENTATION FILE bctx-20231031_pre.xml EX-101.PRE 203909
48 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 661145
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 10-Q | Act: 34 | File No.: 001-40101 | Film No.: 231487795
SIC: 2834 Pharmaceutical Preparations